Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma

Clinical Cancer Research

Volumn 11, Issue 2 I, 2005, Pages 751-755

  Henry, Carolyn J ^a   Buss, Michael S ^b,e   Hellström, Ingegerd ^d,f   Hellström, Karl Erik ^d,f   Brewer, William G ^c,g   Bryan, Jeffrey N ^a   Siegall, Clay B ^d,h  

^a UNIVERSITY OF MISSOURI   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c AUBURN UNIVERSITY   (United States)

^d BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^e Veterinary Specialty Services   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g Affiliated Animal Care   (United States)

^h SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DEXAMETHASONE; IMMUNOTOXIN; IMMUNOTOXIN BR96 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY PSEUDOMONAS EXOTOXIN 40 CONJUGATE; PSEUDOMONAS EXOTOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BLOOD GROUP LEWIS SYSTEM; BREAST CARCINOMA; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LUNG CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECTUM CARCINOMA; VOMITING; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; DOGS; FEMALE; IMMUNOTHERAPY; IMMUNOTOXINS; LEWIS BLOOD-GROUP SYSTEM; LUNG NEOPLASMS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; RECTAL NEOPLASMS;

EID: 12244265087     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hellström I, Garrigues HJ, Garrigues U, Hellström KE. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res 1990;50:2183-90.
2. Garrigues J, Anderson J, Hellström KE, Hellström I. Anti-tumor antibody BR96 blocks cell migration and binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes. J Cell Biol 1994;125:129-42.
3. y specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes. Am J Pathol 1993;142:607-22.
4. Trail PA, Willner D, Lasch SJ, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993; 261:212-15.
5. Trail PA, Willner D, Bianchi AB, et al. Enhanced antitumor activity of Paclitaxel in combination with the anti-carcinoma immunoconjugate BR96-doxorubicin. Clin Cancer Res 1999;5:3632-8.
6. Hellström I, Hellström KE, Senter PD. Development and activities of the BR96-doxorubicin immunoconjugate. In: Hall WA, editor. Methods in Molecular Biology, Immunotoxin Methods and Protocols. Vol. 166. Totowa NJ: Humana Press Inc.; 2001. p. 3-16.
7. Wahl AF, Donaldson KL, Mixan BJ, Trail PA, Siegall CB. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin. Int J Cancer 2001;93:590-600.
8. Friedman PN, McAndrew SJ, Gawlak SL, et al. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. Cancer Res 1993;53:334-9.
9. Siegall CB, Chace D, Mixan B, et al. In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats. J Immunol 1994;152:2377-84.
10. Friedman PN, Chace DF, Trail PA, Siegall CB. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts. J Immunol 1993;150:3054-61.
11. Sternberger LA. The unlabeled antibody peroxidase-antiperoxidase (PAP) method. In: Immunocytochemistry. New York: John Wiley and Sons, Inc.; 1979. p. 104-69.
12. Garrigues HJ, Tilgen W, Hellström I, Franke W, Hellström KE. Detection of a human melanoma-associated antigen, p97, in histological sections of primary human melanomas. Int J Cancer 1982;29:511-5.
13. Siegall CB, Haggerty HG, Warner GL, et al. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4-Ig enhances antitumor efficacy. J Immunol 1997;159:5168-73.
14. Chun R, Garrett L, MacEwen EG. Cancer chemotherapy. In: Withrow SJ, MacEwen EG, editors. Small animal clinical oncology. 3rd ed. Philadelphia: WB Saunders Co.; 2001. p. 92-118.
15. Pastan I, Pai LH, Brinkman U, FitzGerald D. Recombinant immunotoxins. Breast Cancer Res Treat 1996;38:3-9.
16. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 2000;18:781-92.
17. Susaneck SJ, Allen TA, Hoopes J, Withrow SJ, Macy DW. Inflammatory mammary carcinoma in the dog. J Am Anim Hosp Assoc 1983;19:971-6.
18. Perez-Alenza MD, Tabanera E, Pena L. Inflammatory mammary carcinoma in dogs: 33 cases (1995-1999). J Am Vet Med Assoc 2001; 219:1110-4.
19. Pai LH, Pastan I. Immunotoxin therapy for cancer. J Am Med Assoc 1993;269:78-81.
20. Pastan I, FitzGerald D. Recombinant toxins for cancer treatment. Science 1991;254:1173-7.
21. Pai LH, Bookman MA, Ozols RF, et al. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 1991;9:2095-103.
22. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res 2000;6:326-34.